Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
Portfolio Pulse from Lara Goldstein
Reunion Neuroscience (NASDAQ:REUN) has entered into a definitive arrangement with investment firm MPM BioImpact for an all-cash acquisition valued at approximately $13.1 million. Shareholders will receive $1.12 per share, a 43.1% premium over the trailing 30-trading-day volume weighted average price. The deal is expected to close in Q3 2023.
June 01, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reunion Neuroscience is being acquired by MPM BioImpact in an all-cash deal valued at $13.1 million. Shareholders will receive $1.12 per share, a 43.1% premium. The deal is expected to close in Q3 2023.
The acquisition of Reunion Neuroscience by MPM BioImpact is a significant event for the company and its shareholders. The all-cash deal valued at $13.1 million offers a 43.1% premium over the trailing 30-trading-day volume weighted average price, which is likely to have a positive impact on the stock price in the short term. The deal is expected to close in Q3 2023, after which Reunion will no longer be traded or listed on any public securities exchange.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100